| Prev Close | 172.93 |
| Day Low/High | 170.57 / 173.47 |
| 52 Wk Low/High | 152.16 / 201.23 |
| Avg Volume | 5.09M |
| Exchange | NASDAQ |
| Shares Outstanding | 668.27M |
| Market Cap | 115.56B |
| EPS | 2.70 |
| P/E Ratio | 64.29 |
| Div & Yield | 5.28 (2.72%) |
The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BAM, BBBY, LMNR, TCAP Downgrades: AMGN, HQCL, HRZN, MRCC, NMFC, PAR, PKOH, SHLM, SSB, TEDU, UBSI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.
This Approval was Based on the Largest International Trial Ever Conducted for the Prevention of Skeletal-Related Events in Multiple Myeloma Patients
BLINCYTO is the First-and-Only FDA-Approved Therapy for Minimal Residual Disease
Recommended Label Includes New Indication Based on the Repatha Cardiovascular Outcomes Study (FOURIER)
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab)
Research Presented at American College of Cardiology's 67th Annual Scientific Session Reveals More Than 110,000 Cardiovascular Events a Year Could Occur in High-Risk Patients With Cardiovascular Disease who are Rejected Access
Jim Cramer highlights DowDuPont, Sorrento Therapuetics, Lockheed Martin, ZAGG, Worldpay, Pattern Energy, AMC Networks.
Trade wars, tariffs, Gary Cohn's resignation... yes, all shocking. But investors need to buy what's working, says Jim Cramer.
Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.
Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.
Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?
Application Based on Data From Largest International Multiple Myeloma Trial for the Prevention of Skeletal-Related Events Ever Conducted
First-Ever Application to be Submitted for an MRD Positive Indication
XGEVA Successfully Met Primary Endpoint of Non-Inferiority Versus Zoledronic Acid in Delaying Time to First On-Study Skeletal-Related Event
The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.
TheStreet's Jim Cramer and Marc Chaikin, of Chaikin Analytics, spent an hour together at our offices talking all things markets. Listen to the whole conversation below. In the except above, they discuss Amgen and why Chaikin says to be careful of the stock.
The good news is that volatility is increasing. The bad news, for some, is that it moves in both directions.
This will be the ninth consecutive year when the big game tops that 100 million-viewers mark.
Label Variation to Include Overall Survival Data From Phase 3 ENDEAVOR Trial
Jim Cramer says watch out for those earnings reports this week, and use any pullback to put some money into a good index fund. You won't regret it.
